Robert Litman
Rockville, MDNPI 1114041274
Payments from drug & device makers
Across 661 payments — averaging $22,347 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3.1M
- Vanda Pharmaceuticals Inc.$2.5M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2.5M
- Sunovion Pharmaceuticals Inc.$2M
- Takeda Pharmaceuticals U.S.A., Inc.$1.5M
- Roche TCRC, Inc.$1.2M
- plus $2.1M from 16 others
Across 1 payment — averaging $107.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$107
What the payments were for
- Consulting fees$5,1159%
- Speaking & faculty fees$48,15580%
- Travel & lodging$4,9728%
- Food & beverage$1,6523%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 207 | $3,092,894 |
| Vanda Pharmaceuticals Inc. | 14 | $2,548,126 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $2,471,356 |
| Sunovion Pharmaceuticals Inc. | 109 | $1,961,230 |
| Takeda Pharmaceuticals U.S.A., Inc. | 65 | $1,472,517 |
| Roche TCRC, Inc. | 10 | $1,167,106 |
| Hoffmann-la Roche Limited | 30 | $1,036,313 |
| Janssen Research & Development, LLC | 42 | $434,691 |
| Teva Pharmaceuticals USA, Inc. | 32 | $155,950 |
| Biogen | 4 | $149,722 |
| Sage Therapeutics, LLC | 19 | $87,280 |
| Johnson & Johnson | 47 | $48,321 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31,298 |
| Biohaven Pharmaceuticals, Inc. | 3 | $26,463 |
| Sumitomo Pharma America, Inc. | 58 | $24,789 |
| Genentech, Inc. | 4 | $23,372 |
| Merck | 1 | $15,213 |
| Jazz Pharmaceuticals Inc. | 5 | $13,970 |
| H. Lundbeck A S | 1 | $5,670 |
| F. Hoffmann-la Roche AG | 1 | $2,590 |
| Novartis | 2 | $2,532 |
| Otsuka America Pharmaceutical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$47,818
- VRAYLAR$7,880
- NURTEC ODT$134
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluoxetine Hcl | 12 | $224 |
| Trihexyphenidyl Hcl | 13 | $193 |
| Risperidone | 13 | $183 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.